Boundless Bio, Inc.(BOLD) - 2024 Q3 - Quarterly Results

Financial Performance - Cash position as of September 30, 2024, is $167.1 million, providing an operating runway into the fourth quarter of 2026[6] - Net loss for Q3 2024 totaled$ 16.5 million, compared to a net loss of $13.2 million in Q3 2023, indicating a 25% increase in losses[6] - Total operating expenses for Q3 2024 were$ 18.7 million, compared to $15.0 million in Q3 2023, marking an increase of 25.5%[13] - Accumulated deficit as of September 30, 2024, was$ 185.0 million, compared to $136.1 million at the end of 2023[13] Research and Development - Research and development (R&D) expenses for Q3 2024 were$ 14.1 million, up from $11.6 million in Q3 2023, representing a 21.5% increase[6] - Initial proof-of-concept data for BBI-355 and BBI-825 clinical trials is expected in the second half of 2025[3][4] - The company is advancing its third ecDTx program, ecDTx 3, through lead optimization[4] General and Administrative Expenses - General and administrative (G&A) expenses for Q3 2024 were$ 4.6 million, compared to $3.3 million in Q3 2023, reflecting a 39.4% increase[6] Assets and Financial Position - Total assets as of September 30, 2024, were$ 175.1 million, up from $129.9 million at the end of 2023[13] Clinical Trials and Diagnostics - ECHO, the proprietary diagnostic for detecting ecDNA amplified oncogenes, is currently being used in the BBI-355 POTENTIATE trial[5]